omecamtiv mecarbil
Jump to navigation
Jump to search
Indications
* in addition to standard systolic heart failure treatment
* well tolerated, may be of benefit[2]
Dosage
- 25 mg, 37.5 mg, or 50 mg twice dailyt
Mechanism of action
- selective cardiac myosin activator
More general terms
References
- ↑ Teerlink JR, Diaz R, Felker GM et al Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. N Engl J Med. 2020 Nov 13. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33185990
- ↑ 2.0 2.1 Felker GN, Solomon CD, Claggett B et al Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure. A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. JAMA Cardiol. 2022;7(1):26-34 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34643642 PMCID: PMC8515258 (available on 2022-10-13) https://jamanetwork.com/journals/jamacardiology/fullarticle/2785151